Clinical Study of Partially Hydrolysed Protein Infant Formula on Trans-epidermal Water Loss (TEWL)
- Conditions
- Skin ConditionAtopic Dermatitis
- Interventions
- Dietary Supplement: Partially Hydrolysed Whey FormulaDietary Supplement: Intact Cow's Milk Protein Formula
- Registration Number
- NCT04763512
- Lead Sponsor
- Société des Produits Nestlé (SPN)
- Brief Summary
This is a single-centre, prospective, randomized, open-label, controlled trial of 200 infants 42±7 days of age. Subjects will be randomized to one of two open label feeding intervention group:
* Intact Cow's Milk Protein Formula Group (CMFG) (n = 100) or
* Partially Hydrolysed Whey Formula Group (pHFG) (n = 100).
- Detailed Description
Atopic dermatitis (AD) affects 15 - 30% of children. Approximately 45% of these cases have an onset within the first 6 months of life and 60% develop within the first year (Bieber 2010). Besides environmental factors, the aetiology of AD has been found to be associated with genetic variants involved in skin barrier function defect and inflammation, leading to dry skin with increases in susceptibility to environmental exposures (Bieber 2008).
Partially hydrolysed cow's milk (whey) protein infant formula (pHF) has been shown to be effective in prevention of AD, both among at-risk and healthy infants (Exl, Deland et al. 2000, von Berg, Koletzko et al. 2003, Jingrana and Dunjina 2015). However, to date there are no published pediatric data to document the relationship between partially hydrolysed protein formulas and skin barrier function, specifically evaluating the effect of pHF on Trans-epidermal Water Loss (TEWL) among infants. Therefore, this study aims to evaluate the effect on skin barrier function as measured by TEWL and we hypothesize that infants consuming partially hydrolysed starter formula will have lower TEWL when compared infants consuming intact cow's milk protein starter formula.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
- Infants 42± 7 days of age at enrolment (date of birth = age 0).
- Infants who have been born full-term gestational birth (≥ 37 completed weeks of gestation) and having a birth weight ≥ 2.5 kg and ≤ 4.5 kg.
- Parents /caregivers must agree to follow study procedures and recommended skincare routines, such as avoidance of moisturizers or other skincare products on the primary sites of interest.
- Parent(s) must have already independently elected before enrolment to formula feed and less than 30% of intake will be from breastmilk.
- Known and diagnosed cow's milk protein allergy/intolerance.
- Infants currently using or have ever used partially hydrolysed protein formulas.
- Infants who have ever used topical corticosteroids, calcineurin inhibitors and/or any other physician-recommended treatments for skin conditions after birth.
- Infants who have been introduced to complementary foods.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Partially Hydrolysed Whey Formula Group (pHFG) Partially Hydrolysed Whey Formula All enrolled subjects will be fed Stage 1 pHF libitum for 4 months. Thereafter, they will switch to Stage 2 pHF at age 6 months (Study Month 4) and to Stage 3 pHF at age 12 months (Study Month 9) and continue until age 18 months (Study Month 15). Thereafter, they will discontinue study formula and complete the study. Intact Cow's Milk Protein Formula Group (CMFG) Intact Cow's Milk Protein Formula All enrolled subjects will be fed Stage 1 CMF libitum for 4 months. Thereafter, they will discontinue study formula and complete the study.
- Primary Outcome Measures
Name Time Method Skin barrier function Baseline (age 42 ± 7 days) to Study Month 4 (age 6 months) Change in Trans-epidermal water loss (TEWL)
- Secondary Outcome Measures
Name Time Method Weight Baseline (age 42 ± 7 days) to Study Month 4 (age 6 months) - in both randomized groups and until Study Month 15 (age 18 months) in pHF group only Weight in grams and corresponding Z-score according to WHO reference standards and/or local standardized growth charts will be calculated.
Length Baseline (age 42 ± 7 days) to Study Month 4 (age 6 months) - in both randomized groups and until Study Month 15 (age 18 months) in pHF group only Length in centimeters and corresponding Z-score according to WHO reference standards and/or local standardized growth charts will be calculated.
Head Circumference Baseline (age 42 ± 7 days) to Study Month 4 (age 6 months) - in both randomized groups and until Study Month 15 (age 18 months) in pHF group only Head circumference in centimeters and corresponding Z-score according to WHO reference standards and/or local standardized growth charts will be calculated.
Infant health-related quality of life Baseline (age 42 ± 7 days) to Study Month 4 (age 6 months) - in both randomized groups and until Study Month 15 (age 18 months) in pHF group only Assessed through the Happy Growth Index Questionnaire with each question rated on a Likert scale from strongly disagree to strongly agree.
Incidence and severity of Atopic Dermatitis (AD) and other allergic manifestations (CMF group) aseline (age 42 ± 7 days) to Study Month 4 (age 6 months) - in both randomized groups and until Study Month 15 (age 18 months) in pHF group only Incidence will be gathered from standard Adverse Event (AE) reporting. Atopic Dermatitis (AD) will be diagnose based on the Williams diagnostic criteria of International Study of Asthma and Allergies in Childhood (ISAAC). Severity of AD will be assessed using the SCORing Atopic Dermatitis (SCORAD) index, which consists of the extent and intensity of the disorder and subjective symptoms.
Infant gut comfort Baseline (age 42 ± 7 days) to Study Month 4 (age 6 months) Using the Infant Gastrointestinal Symptom Questionnaire (IGSQ)-13.
Toddler gut comfort Study Month 9 (age 12 months) and Study Month 15 (age 18 months) Using the Toddler Gut Comfort Questionnaire.
Stool consistency Baseline (age 42 ± 7 days) to Study Month 4 (age 6 months) Parents will record for 3 consecutive days after each bowel movement in a 3-Day Stool Diary the stool consistency on a validated 5-point scale from 1-watery to 5-hard.
Formula acceptance and satisfaction Baseline (age 42 ± 7 days) to Study Month 4 (age 6 months) - in both randomized groups and until Study Month 15 (age 18 months) in pHF group only Formula intake, acceptability and satisfaction recorded using the Milk Intake and Satisfaction Questionnaire.
Safety assessment: Adverse events (AEs) Baseline (age 42 ± 7 days) to Study Month 4 (age 6 months) - in both randomized groups and until Study Month 15 (age 18 months) in pHF group only Using standard adverse events (AEs) reporting for safety assessment.
Trial Locations
- Locations (1)
Shanghai Tonxin Pediatric Clinic Co. Ltd
🇨🇳Shanghai, Shanghai, China